An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Veracyte, Inc. (NASDAQ: VCYT) has appointed Dr. Joshua Klopper as its new medical director of Endocrinology. Dr. Klopper, a distinguished endocrinologist with expertise in thyroid nodules and cancer, previously served at the Colorado Permanente Medical Group. His clinical research experience includes significant contributions to the Afirma genomic classifier, supporting Veracyte’s mission to enhance patient outcomes through genomic diagnostics. This leadership addition aims to strengthen Veracyte's capabilities in thyroid health management.
Positive
Dr. Klopper's extensive experience in thyroid cancer and nodules may enhance Veracyte's diagnostic capabilities.
His familiarity with Veracyte's Afirma genomic classifier could accelerate the adoption of their diagnostic solutions.
Negative
Potential concerns about continuity as a new medical director may require adjustments in strategy and team dynamics.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Richard T. Kloos, M.D., Veracyte’s executive medical director.
Joshua Klopper, M.D. (Photo: Business Wire)
“Dr. Klopper is an exceptional addition to Veracyte’s world-class medical team,” said Dr. Kloos. “He was an investigator on the study that demonstrated the clinical utility of our original Afirma genomic classifier for reducing unnecessary surgeries in thyroid nodule evaluation, so is extremely knowledgeable about the test and its clinical value. More broadly, his extensive clinical and research experience, particularly in thyroid nodule and thyroid cancer management, will help us achieve our vision of improving outcomes for patients all over the world at every step of their journey.”
Dr. Klopper most recently served as regional service chief of the Colorado Permanente Medical Group (CPMG) of Kaiser Permanente. Prior to his work at CPMG, Dr. Klopper was a full-time faculty member in the Division of Endocrinology at the University of Colorado School of Medicine, where he specialized in thyroid nodule and thyroid cancer evaluation and management. Dr. Klopper was the co-director of the Endocrine Society Introductory Hands-On Thyroid Ultrasound Workshop for five years and has served on the American Thyroid Association board of directors.
Dr. Klopper graduated from the Emory University School of Medicine. He completed his internship and residency in internal medicine at the University of Colorado Health Sciences Center (UCHSC). He subsequently completed both a postdoctoral research fellowship in the Endocrinology Division of UCHSC and an endocrinology fellowship.
“Over the course of my nearly 20 years providing care for patients with thyroid nodules and thyroid cancer, I’ve witnessed the growing, positive impact of genomic information and technologies,” said Dr. Klopper. “I am thrilled to join the truly impressive medical team at Veracyte, a company that is leading the way in this area to improve patient outcomes and the standard of care.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.
Tracy Morris Vice President of Corporate Communications & Investor Relations 650-380-4413
tracy.morris@veracyte.com
Source: Veracyte, Inc.
FAQ
What is the significance of Dr. Joshua Klopper's appointment at Veracyte?
Dr. Klopper's appointment is significant as he brings extensive experience in endocrinology, particularly in thyroid care, which aligns with Veracyte's focus on genomic diagnostics.
When did Veracyte announce Dr. Klopper's appointment?
Veracyte announced Dr. Klopper's appointment as medical director of Endocrinology on September 1, 2021.
How might Dr. Klopper's experience impact Veracyte's business?
Dr. Klopper's expertise in thyroid diagnostics may enhance Veracyte's product offerings and improve patient outcomes, potentially driving business growth.
What previous roles did Dr. Klopper hold before joining Veracyte?
Before joining Veracyte, Dr. Klopper was the regional service chief at the Colorado Permanente Medical Group and a faculty member at the University of Colorado School of Medicine.
